tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Harrow Health Launches $250 Million Senior Notes Offering

Story Highlights
Harrow Health Launches $250 Million Senior Notes Offering

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Harrow Health ( (HROW) ).

On September 5, 2025, Harrow, Inc. entered into a commitment letter with Fifth Third Bank for a new $40 million revolving credit facility. Subsequently, on September 8, 2025, Harrow announced the launch of a private offering to sell $250 million in senior unsecured notes due 2030, with proceeds intended to redeem existing notes, prepay loans, and fund corporate purposes. Additionally, Harrow issued a conditional notice to redeem its 2027 notes, contingent on the offering’s completion, and plans to redeem its 2026 notes. The company also expressed interest in acquiring the remaining equity of Melt Pharmaceuticals, Inc., subject to certain conditions.

The most recent analyst rating on (HROW) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.

Spark’s Take on HROW Stock

According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.

Harrow Health’s overall stock score is driven by strong technical indicators and positive earnings call highlights, including strategic alliances and revenue growth. However, significant financial performance challenges, particularly in profitability and cash flow, weigh heavily on the score. The negative P/E ratio further impacts the valuation, limiting the stock’s attractiveness.

To see Spark’s full report on HROW stock, click here.

More about Harrow Health

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases.

Average Trading Volume: 498,973

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.37B

For detailed information about HROW stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1